US20110262385A1 - Use of interleukin-22 in the treatment of fatty liver disease - Google Patents

Use of interleukin-22 in the treatment of fatty liver disease Download PDF

Info

Publication number
US20110262385A1
US20110262385A1 US12/672,274 US67227408A US2011262385A1 US 20110262385 A1 US20110262385 A1 US 20110262385A1 US 67227408 A US67227408 A US 67227408A US 2011262385 A1 US2011262385 A1 US 2011262385A1
Authority
US
United States
Prior art keywords
fatty liver
cells
liver
use according
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/672,274
Other languages
English (en)
Inventor
Yu Liang HUANG
Zhi Hua Huang
Qi Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generon Shanghai Corp Ltd
Original Assignee
Generon Shanghai Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generon Shanghai Corp Ltd filed Critical Generon Shanghai Corp Ltd
Assigned to GENERON (SHANGHAI) CORPORATION reassignment GENERON (SHANGHAI) CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HUANG, YU LIANG, HUANG, ZHI HUA, SUN, QI
Publication of US20110262385A1 publication Critical patent/US20110262385A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • Fatty liver is a disease in which excessive amounts of lipids accumulate in the liver cells. Normally lipids account for 3%-4% of the total weight of the liver. If the amount of lipid goes beyond 5%, a fatty liver forms. Lipids may comprise up to 40%-50% of the liver weight in severe fatty liver diseases. Fatty liver mainly comes from the disorder of lipid metabolism of the liver. The main form of lipid in the liver is triglyceride, which is characterized by macrovesicular steatosis. Fatty liver can lead to fibrosis of liver, cirrhosis and hepatocellular carcinoma. In US, around 31% of the adults are indicated to have fatty liver by NMR.
  • available clinical therapeutic strategies include, antioxidant, e.g., vitamin C, vitamin E; compounds in methione metabolism, e.g., betaine; metformin, which can sensitize insulin, other similar medications include: thiazolidinediones (TZD), inhibitors of angiotension II receptor; urodeoxycholic acid, which has the effect of cell protection, anti-apoptosis and regulation of immunity; pentoxifylline, which can act by inhibiting inflammatory factors such as tumor necrosis factor (TNF)- ⁇ ; other medicaments such as troglitazone, rosiglitazone and pioglitazone. All the therapeutic methods are not satisfactory.
  • TNF tumor necrosis factor
  • IL-22 functions by binding to its receptor IL-22R1 and IL-22R2.
  • IL-22R1 is specific receptor for IL-22, which is mainly expressed in skin, kidney, digestive system (pancreas, intestine, liver, large intestine, and colon) and respiratory system (lung, bronchus).
  • IL-22R1 is specific receptor for IL-22, which is mainly expressed in skin, kidney, digestive system (pancreas, intestine, liver, large intestine, and colon) and respiratory system (lung, bronchus).
  • A Oil Red O stained liver section of ob/ob mice (control);
  • FIG. 8A shows that treatment of high fat diet-induced FLD rats reduced body weight
  • FIG. 12 shows electron microscopy imaging of liver sections showing the size of fat droplets in hepatocytes.
  • IL-22 refers to a protein, which has essentially the same amino acid sequence as the human/murine IL-22 as described by Dumoutier in U.S. Pat. No. 6,359,117 and the same biological activity as natural IL-22.
  • IL-22 of the present invention includes but is not limited to human IL-22, recombinant human IL-22, murine IL-22 and recombinant murine IL-22.
  • subject refers to mice, human or other mammal animals.
  • therapeutically effective amount refers to an amount of IL-22 which can achieve the goal of therapy. It is to be understood by one of ordinary skill in the art that, therapeutically effective dose may change, depending on the routes of administration, the types of other ingredients used and the combination with other medicaments.
  • IL-22 of the present invention is expressed by recombinant gene clone technique.
  • the expression system includes prokaryotic cells, yeast or higher eukaryotic cells.
  • Suitable prokaryotic cell includes, but is not limited to G + or G ⁇ bacteria, such as E. coli .
  • Available strains of E. coli includes K12MM294 (ATCC 31,446), X1776 (ATCC 31,537), W3110 (ATCC 27,325) and K5772 (ATCC 53,635) etc.
  • Other suitable prokaryotic expression system includes, but is not limited to Erwinia, Klebsiella, Proteus, Salmonella , such as Salmonella typhimurium, Serratia such as Serratia marcescans, Shigella, B. subtilis, B. licheniformis, Pseudomonas such as P. aeruginosa and Streptomyces.
  • E. coli W3110 is preferred since it is often used as the host cell for
  • Host cells used to express glycosylated IL-22 of the present invention are mainly derived from multicellular organism.
  • invertebrate include insect, such as Drosophila S2 and Spodoptera Sf9, plant cells.
  • Suitable mammalian cells include Chinese Hamster Ovary (CHO), COS cells, in particular, SV40-transformed CV1 cell line (COS-7, ATCC CRL 1651); human embryo kidney cell line 293 (Graham et al., J. Gen Virol., 36:59 (1997)); CHO/-DHFR (Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77:4216 (1980)); murine Sertoli cell (TM4, Mather, Biol.
  • nucleic acid micro-injection electroporation
  • bacterial protoplast fusion with intact cells or polycations
  • polycations such as polybrene, polyornithine
  • Keown et al. Methods in Enzymology, 185:527-537 (1990) and Mansour et al., Nature, 336:348-352 (1988).
  • Some other inducible yeast promoter can regulate transcription according to different growing conditions, including promoters for alcohol dehydrogenase 2, isocytochrome c, acid phosphatase, degrading enzymes related to degradation of nitrogen, Metallothionein, Glyceraldehyde-3-Phosphate, degrading enzymes of maltose and galactose.
  • promoters for alcohol dehydrogenase 2, isocytochrome c, acid phosphatase, degrading enzymes related to degradation of nitrogen, Metallothionein, Glyceraldehyde-3-Phosphate, degrading enzymes of maltose and galactose Detailed description of vectors and promoters suitable for yeast expression system can be seen in EP 73,657.
  • Enhancer is a kind of cis-acting element of DNA molecules, usually 10-300 bp, which can enhance the transcription of DNA molecules by acting on the promoters. Numbers of enhancers known enhancers are from mammalian gene, e.g. haptoglobin, elastase, albumin, ⁇ -fetoprotein and insulin.
  • the IL-22 encoding DNA sequence of the present invention can be used in gene therapy.
  • Gene therapy includes traditional therapy, which has long term effects after one time therapy and administration of gene therapy drugs, in which effective DNA or mRNA are administered one or several times.
  • Antisense RNA or DNA may also be used as gene therapy drugs to block the expression of some genes. It has been demonstrated that antisense oligonucleotide can act as inhibitors in cells, although they are only adsorbed by cell membrane to a limited extent and have a low concentration in cells (Zamecnik et al., Proc. Natl. Acad. Sci. USA 83:4143-4146 [1986]).
  • the absorbance of oligonucleotides may be improved by modification, such as substituent of the negative charged phosphodiester by balance charged groups.
  • micro-capsule containing IL-22 of the present invention can be used as sustained release system.
  • Sustained release micro-capsule system of recombinant protein has been successfully applied to rhGH, rhIFN, IL-2 and MNrgp 120 (Johnson et al., Nat. Med., 2:795-799 (1996); Yasuda, Biomed. Ther 27:1221-1223 (1993); WO 97/03692, WO 96/40072, WO 96/07399; U.S. Pat. No. 5,654,010).
  • IL-22 has the effect of treating fatty liver diseases. 2. IL-22 has the effect of decreasing levels of transaminases (especially, aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT).
  • transaminases especially, aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT).
  • Both human IL-22 and murine IL-22 were verified by DNA sequencing, as shown in FIG. 1 and FIG. 2 .
  • E. coli strain BL21(+) was used to express the recombinant protein.
  • the E. coli cells were homogenized under high pressure.
  • IL-22 inclusion bodies were obtained by centrifugation and washed with buffers (Tris-HCl 50 mM, NaCl 100 mM, EDTA 1 mM, DTT 1 mM, and sodium deoxycholate 0.5%) completely.
  • Inclusion bodies were solubilized in 8M urea, 50 mM Mes, 10 mM EDTA, and 0.1 mM DTT, pH 6.5.
  • Inclusion bodies was refolded 4 times for 20 hours in 100 mM Tris-HCl, 2 mM EDTA, 0.5 M L-arginine, 1 mM reduced glutathion, and 0.1 mM oxidized glutathion, pH 8. The mixture was then concentrated and purified using a Superdex75 (Amersham) column chromatography. The protein was eluted with 20 mM Tris-HCl, 50 mM NaCl, pH 7. The purity of IL-22 was determined by SDS-PAGE (>95%) as shown in FIG. 3 and FIG. 4 . IL-22 protein aliquot was stored at ⁇ 80° C.
  • the recombinant murine IL-22 obtained in example 2 was injected to obese ob/ob mice (8-12 weeks, 35-50 g) at a dose of 300 ⁇ g/kg/d for 14 days. Same amount of vehicle solution (0.1% BSA, PBS) was injected to the mice in control groups. The animals were sacrificed at day 15 and the serum was collected. Levels of serum ALT and AST were determined. The results are shown in FIG. 5 .
  • the recombinant murine IL-22 obtained in example 2 was injected to obese ob/ob mice (8-12 weeks, 35-50 g) at a dose of 300 ⁇ g/kg/d for 14 days. Same amount of vehicle solution (0.1% BSA, PBS) was injected to the mice in control groups. The animals were sacrificed at day 15. The liver was collected and fixed in 10% formalin. Tissue section was stained with Hematoxylin-Eosin. The results were shown in FIG. 6 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US12/672,274 2007-08-06 2008-08-01 Use of interleukin-22 in the treatment of fatty liver disease Abandoned US20110262385A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNCN200710044592.7 2007-08-06
CN2007100445927A CN101361968B (zh) 2007-08-06 2007-08-06 白介素-22在治疗脂肪肝中的应用
PCT/US2008/071859 WO2009020844A1 (fr) 2007-08-06 2008-08-01 Utilisation de l'interleukine-22 dans le traitement de la stéatose hépatique

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/071859 A-371-Of-International WO2009020844A1 (fr) 2007-08-06 2008-08-01 Utilisation de l'interleukine-22 dans le traitement de la stéatose hépatique

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/483,175 Division US20140377222A1 (en) 2007-08-06 2014-09-11 Use of interleukin-22 in the treatment of fatty liver disease

Publications (1)

Publication Number Publication Date
US20110262385A1 true US20110262385A1 (en) 2011-10-27

Family

ID=40341656

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/672,274 Abandoned US20110262385A1 (en) 2007-08-06 2008-08-01 Use of interleukin-22 in the treatment of fatty liver disease
US14/483,175 Abandoned US20140377222A1 (en) 2007-08-06 2014-09-11 Use of interleukin-22 in the treatment of fatty liver disease
US15/694,670 Active US10786551B2 (en) 2007-08-06 2017-09-01 Use of interleukin-22 in the treatment of fatty liver disease

Family Applications After (2)

Application Number Title Priority Date Filing Date
US14/483,175 Abandoned US20140377222A1 (en) 2007-08-06 2014-09-11 Use of interleukin-22 in the treatment of fatty liver disease
US15/694,670 Active US10786551B2 (en) 2007-08-06 2017-09-01 Use of interleukin-22 in the treatment of fatty liver disease

Country Status (7)

Country Link
US (3) US20110262385A1 (fr)
EP (1) EP2185202B1 (fr)
JP (1) JP5546453B2 (fr)
CN (1) CN101361968B (fr)
AU (1) AU2008284116B2 (fr)
CA (1) CA2695734C (fr)
WO (1) WO2009020844A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273108B2 (en) 2010-05-25 2016-03-01 Generon (Shanghai) Corporation Ltd. Recombinant human G-CSF dimer and use thereof for the treatment of neurological diseases
US9352024B2 (en) 2011-12-27 2016-05-31 Generon (Shanghai) Corporation Ltd. Uses of interleukin-22(IL-22) in treating and preventing nerve damage diseases or neurodegenerative diseases
US9629898B2 (en) 2010-08-31 2017-04-25 Generon (Shanghai) Corporation, Ltd. Use of interleukin-22 in treating viral hepatitis
US9642917B2 (en) 2011-07-25 2017-05-09 Generon (Shanghai) Corporation, Ltd. Use of G-CSF dimer in preparation of medicament for treatment of neurodegenerative diseases
US10543169B2 (en) 2013-11-07 2020-01-28 Generon (Shanghai) Corporation Ltd. Use of IL-22 dimer in manufacture of a medicament for intravenous administration
US10695406B2 (en) 2014-05-27 2020-06-30 The University Of Queensland Modulation of cellular stress using a B-cell oxidative and/or endoplasmic reticulum stress inhibitor and a targeting agent
US10786551B2 (en) 2007-08-06 2020-09-29 Generon (Shanghai) Corporation Ltd. Use of interleukin-22 in the treatment of fatty liver disease
US11510966B2 (en) 2016-04-15 2022-11-29 Evive Biotechnology (Shanghai) Ltd Use of IL-22 in treating necrotizing enterocolitis

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2848656C (fr) 2010-09-15 2017-10-10 Randall J. Mrsny Systemes et procedes d'administration d'agents biologiquement actifs par le biais de sequences vectrices derivees de toxine bacterienne
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
TR201809571T4 (tr) 2013-03-15 2018-07-23 Hoffmann La Roche Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
BR112016025866A2 (pt) 2014-05-07 2017-12-12 Applied Molecular Transp Llc composição farmacêutica, método para tratar uma doença anti-inflamatória em um indivíduo, método para tratar uma doença autoimune em um indivíduo, método para tratar um câncer em um indivíduo, uso de uma molécula de fusão que não ocorre naturalmente, método para tratar um distúrbio metabólico em um indivíduo, método para tratar uma doença hepática gordurosa em um indivíduo, método para tratar um distúrbio de deficiência de hormônio de crescimentoem um indivíduo, e, polinucleotídeo que codifica uma molécula de fusão
CA2979033A1 (fr) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methodes de traitement de la steatose hepatique non alcoolique et/ou de la lipodystrophie
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy
SG11202104721RA (en) 2018-11-07 2021-06-29 Applied Molecular Transport Inc Delivery constructs for transcytosis and related methods
IL282986B2 (en) 2018-11-07 2024-01-01 Applied Molecular Transport Inc Colics-derivative carriers for oral administration of heterologous cargo
WO2021034727A1 (fr) 2019-08-16 2021-02-25 Applied Molecular Transport Inc. Compositions, formulations et production et purification d'interleukines
WO2022050230A1 (fr) * 2020-09-03 2022-03-10 学校法人埼玉医科大学 Composition inhibant l'activation d'un récepteur de l'adénosine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006073508A1 (fr) * 2005-01-04 2006-07-13 Generon Corporation Utilisation de l'il-22 pour le traitement de troubles metaboliques

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4849227A (en) 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
WO1989005859A1 (fr) 1987-12-21 1989-06-29 The Upjohn Company Transformation par l'agrobacterium de graines de plantes de germination
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE68927344T2 (de) 1989-04-28 1997-02-20 Rhein Biotech Proz & Prod Gmbh Hefezellen der Gattung-Schwanniomyces
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
ES2151541T3 (es) 1992-12-02 2001-01-01 Alkermes Inc Microesferas que contienen hormona del crecimiento de liberacion prolongada.
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
AU1684195A (en) 1994-02-22 1995-09-04 Georgia Tech Research Corporation Reduction of friction during wire drawing
EP0779806B2 (fr) 1994-09-09 2008-04-16 Takeda Pharmaceutical Company Limited Preparation a liberation prolongee renfermant un sel metal de peptide
DE69614685T2 (de) 1995-06-07 2002-06-27 Alkermes Inc Mittel zur verzögerten freisetzung von menschlichem wachstumshormon
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US6551799B2 (en) * 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US20010023070A1 (en) 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
EP1082433A4 (fr) 1998-05-29 2003-01-02 Human Genome Sciences Inc Interleukine 21 et 22
US6274710B1 (en) 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
JP3769189B2 (ja) 1998-10-26 2006-04-19 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｔ細胞誘導性因子（ｔｉｆ）をコードする単離された核酸分子、コードされたタンパク質およびその使用
US7307161B1 (en) 1999-04-28 2007-12-11 Genetics Institute, Llc Human Gil-19/AE289 polynucleotides
US7226591B2 (en) 2000-05-22 2007-06-05 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
CN1163263C (zh) 2000-01-07 2004-08-25 华中理工大学 一种多肽类药物口腔喷雾剂
GB0024442D0 (en) 2000-10-05 2000-11-22 Isis Innovation Genetic factors affecting the outcome of viral infections
CN1335182A (zh) 2001-08-08 2002-02-13 华中科技大学 胰岛素口腔喷剂及其制备工艺
US6797493B2 (en) 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
EP1511511A4 (fr) 2001-11-06 2006-03-29 Lilly Co Eli Utilisation d'il-19, d'il-22 et d'il-24 pour le traitement des troubles hematopoietiques
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
CN1176137C (zh) 2002-01-15 2004-11-17 泛亚生物技术有限公司 多臂树杈型功能化聚乙二醇制备方法及它在药物中的应用
US7597876B2 (en) 2007-01-11 2009-10-06 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
US20030235561A1 (en) 2002-06-25 2003-12-25 Cell Based Delivery Inc. Vascularized organized tissues and uses thereof
US20050148029A1 (en) 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
EP1748789B1 (fr) 2003-11-05 2010-12-29 Institut de Recherche pour le Développement ( IRD) IL-22 pour la prévention des maladies infectieuses
JP5103022B2 (ja) 2004-02-13 2012-12-19 ノッド ファーマシューティカルズ， インコーポレイテッド リン酸カルシウムナノ粒子のコア、生体分子および胆汁酸を含む粒子、ならびにそれらの製造方法および治療用途
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
JP2008532936A (ja) 2005-02-14 2008-08-21 ワイス インターロイキン−１７ｆ抗体及び他のｉｌ−１７ｆシグナル伝達拮抗物質並びにそれらの使用
US20070099251A1 (en) * 2005-10-17 2007-05-03 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
UA95613C2 (ru) * 2005-11-09 2011-08-25 Уеллстат Терепьютикс Корпорейшн Соединения для лечения расстройсв метаболизма
US20110038854A1 (en) 2006-03-30 2011-02-17 University Of Medicine And Dentistry Of New Jersey Strategy for homo- or hetero-dimerization of various proteins in solution and in cell
WO2007123765A2 (fr) 2006-03-31 2007-11-01 Human Genome Sciences Inc. NEUTROKINE-ALPHA et variant d'epissage de la neutrokine-alpha
US20080031882A1 (en) 2006-06-19 2008-02-07 Liang Spencer C Methods of modulating IL-22 and IL-17
WO2008085229A2 (fr) 2006-11-15 2008-07-17 Arteriocyte Inc. Thérapies cellulaires destinées au traitement d'une maladie hépatique
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
WO2009041734A1 (fr) 2007-09-26 2009-04-02 Kyowa Hakko Kirin Co., Ltd. Anticorps agoniste anti-récepteur de la thrombopoïétine humaine
CN101225110B (zh) 2007-10-23 2010-10-20 中国人民解放军军事医学科学院基础医学研究所 人白细胞介素-22突变体及其构建方法和应用
CN101168049A (zh) * 2007-10-23 2008-04-30 中国人民解放军军事医学科学院基础医学研究所 白介素-22在制备治疗肝病药物中的应用及其制备方法
WO2009062102A2 (fr) 2007-11-07 2009-05-14 Genentech, Inc. Compositions et procédés de traitement de troubles microbiens
US8956605B2 (en) 2009-01-12 2015-02-17 Generon (Shanghai) Corporation Prevention and/or treatment of multiple organ dysfunction syndrome with interleukin-22
US20130121959A1 (en) 2010-01-13 2013-05-16 Joseph R. Maxwell Il-22-fc and hepcidin activity
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
CN103182072B (zh) 2011-12-27 2017-05-03 健能隆医药技术（上海）有限公司 白介素‑22在治疗和预防神经损伤疾病或神经退行性疾病中的用途
TR201809571T4 (tr) 2013-03-15 2018-07-23 Hoffmann La Roche Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
ES2739129T5 (es) 2013-11-07 2024-04-02 Memorial Sloan Kettering Cancer Center IL-22 para uso en el tratamiento de la enfermedad gastrointestinal del injerto contra el huesped
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
CN104623639A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 白介素22二聚体在制备治疗胰腺炎药物中的应用
WO2017181143A1 (fr) 2016-04-15 2017-10-19 Generon (Shanghai) Corporation, Ltd. Utilisation d'il-22 pour le traitement de l'entérocolite nécrosante

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006073508A1 (fr) * 2005-01-04 2006-07-13 Generon Corporation Utilisation de l'il-22 pour le traitement de troubles metaboliques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pan et al. (2004), Cellular and Molecular Immunology, Vol. 1(1), pp43-49. *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10786551B2 (en) 2007-08-06 2020-09-29 Generon (Shanghai) Corporation Ltd. Use of interleukin-22 in the treatment of fatty liver disease
US9273108B2 (en) 2010-05-25 2016-03-01 Generon (Shanghai) Corporation Ltd. Recombinant human G-CSF dimer and use thereof for the treatment of neurological diseases
US9629898B2 (en) 2010-08-31 2017-04-25 Generon (Shanghai) Corporation, Ltd. Use of interleukin-22 in treating viral hepatitis
US9642917B2 (en) 2011-07-25 2017-05-09 Generon (Shanghai) Corporation, Ltd. Use of G-CSF dimer in preparation of medicament for treatment of neurodegenerative diseases
US9352024B2 (en) 2011-12-27 2016-05-31 Generon (Shanghai) Corporation Ltd. Uses of interleukin-22(IL-22) in treating and preventing nerve damage diseases or neurodegenerative diseases
US10543169B2 (en) 2013-11-07 2020-01-28 Generon (Shanghai) Corporation Ltd. Use of IL-22 dimer in manufacture of a medicament for intravenous administration
US11654104B2 (en) 2013-11-07 2023-05-23 Evive Biotechnology (Shanghai) Ltd Use of IL-22 dimer in manufacture of a medicament for intravenous administration
US10695406B2 (en) 2014-05-27 2020-06-30 The University Of Queensland Modulation of cellular stress using a B-cell oxidative and/or endoplasmic reticulum stress inhibitor and a targeting agent
US11510966B2 (en) 2016-04-15 2022-11-29 Evive Biotechnology (Shanghai) Ltd Use of IL-22 in treating necrotizing enterocolitis

Also Published As

Publication number Publication date
EP2185202A4 (fr) 2013-11-06
JP5546453B2 (ja) 2014-07-09
AU2008284116A1 (en) 2009-02-12
AU2008284116B2 (en) 2014-01-09
CA2695734A1 (fr) 2009-02-12
CN101361968B (zh) 2011-08-03
CN101361968A (zh) 2009-02-11
EP2185202A1 (fr) 2010-05-19
JP2010535786A (ja) 2010-11-25
WO2009020844A1 (fr) 2009-02-12
US20140377222A1 (en) 2014-12-25
CA2695734C (fr) 2017-02-14
US10786551B2 (en) 2020-09-29
EP2185202B1 (fr) 2015-05-06
US20180028614A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
US10786551B2 (en) Use of interleukin-22 in the treatment of fatty liver disease
US7718604B2 (en) Use of IL-22 for the treatment of conditions of metabolic disorders
US20230301901A1 (en) Use of il-22 dimer in manufacture of a medicament for intravenous administration
JP6325585B2 (ja) インターロイキン−２２のウイルス性肝炎の治療における応用
HRP20040292A2 (en) USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY
JPH0680584A (ja) グリセンチンを有効成分とする医薬
CN101219208A (zh) 白介素-22的医药用途
JPH03127741A (ja) 悪性腫瘍治療剤

Legal Events

Date Code Title Description
AS Assignment

Owner name: GENERON (SHANGHAI) CORPORATION, CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HUANG, YU LIANG;HUANG, ZHI HUA;SUN, QI;REEL/FRAME:025770/0862

Effective date: 20100205

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION